Literature DB >> 8280479

Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.

N L Paul1, M Marsh, J A McKeating, T F Schulz, P Liljeström, H Garoff, R A Weiss.   

Abstract

We have used Semliki Forest virus (SFV) vectors to express both the human immunodeficiency virus type 1 (HIV-1) envelope precursor gp160 and the cleaved external portion gp120. Expression of the foreign gene in this system is by transfection of recombinant SFV RNA, or by infection with a recombinant SFV virus that has a wide host range. pSFV1-gp120 or pSFV1-gp160 were expressed in baby hamster kidney (BHK) cells and two human cell lines: HeLa cervical carcinoma and MOLT-4 CD4+ T cells. After SFV1-gp120 infection of HeLa cells, 3.3 micrograms of gp120 was secreted into the media by 1 million cells in a 24-hr period. The secreted envelope glycoprotein was recognized by anti-gp120 monoclonal antibodies directed against both linear and conformation-dependent epitopes in different regions of the molecule. The recombinant gp120 also bound to a soluble form of the CD4 receptor. Syncytium formation was observed when MOLT-4 cells were infected with SFV1-gp160. The gp160 expressed by BHK cells induced syncytia during cocultivation with C8166 CD4+ T cells. These data indicate that SFV vectors can be used to produce the HIV-1 envelope glycoproteins to high levels, and that these proteins are correctly processed, folded, and transported to the cell surface. Furthermore, they exhibit functional activity as indicated by their ability to bind to soluble receptor and induce cell-to-cell fusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280479     DOI: 10.1089/aid.1993.9.963

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  14 in total

1.  Recombinant protein production using the Semliki Forest Virus expression system.

Authors:  H D Blasey; K Lundström; S Tate; A R Bernard
Journal:  Cytotechnology       Date:  1997-05       Impact factor: 2.058

2.  Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.

Authors:  F C Verrier; P Charneau; R Altmeyer; S Laurent; A M Borman; M Girard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein.

Authors:  R Bron; P J Klasse; D Wilkinson; P R Clapham; A Pelchen-Matthews; C Power; T N Wells; J Kim; S C Peiper; J A Hoxie; M Marsh
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  A novel self-replicating chimeric lentivirus-like particle.

Authors:  Christy K Jurgens; Kelly R Young; Victoria J Madden; Philip R Johnson; Robert E Johnston
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 5.  Alphavirus-based expression vectors: strategies and applications.

Authors:  I Frolov; T A Hoffman; B M Prágai; S A Dryga; H V Huang; S Schlesinger; C M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease.

Authors:  Myoung-Hwa Lee; Tongguang Wang; Mi-Hyeon Jang; Joseph Steiner; Norman Haughey; Guo-li Ming; Hongjun Song; Avindra Nath; Arun Venkatesan
Journal:  Neurobiol Dis       Date:  2010-12-10       Impact factor: 5.996

7.  Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.

Authors:  Qi Guo; Hsu-Tso Ho; Ira Dicker; Li Fan; Nannan Zhou; Jacques Friborg; Tao Wang; Brian V McAuliffe; Hwei-Gene Heidi Wang; Ronald E Rose; Hua Fang; Helen T Scarnati; David R Langley; Nicholas A Meanwell; Ralph Abraham; Richard J Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  Manipulation of the Semliki Forest virus genome and its potential for vaccine construction.

Authors:  G J Atkins; B J Sheahan; P Liljeström
Journal:  Mol Biotechnol       Date:  1996-02       Impact factor: 2.695

10.  Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Authors:  S P Mossman; F Bex; P Berglund; J Arthos; S P O'Neil; D Riley; D H Maul; C Bruck; P Momin; A Burny; P N Fultz; J I Mullins; P Liljeström; E A Hoover
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.